The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability

Journal of Pharmacological and Toxicological Methods

Volumn 61, Issue 3, 2010, Pages 238-250

  Roche, Michel ^a   Renauleaud, Céline ^a   Ballet, Véronique ^a   Doubovetzky, Michel ^a   Guillon, Jean Michel ^a  

^a SANOFI   (France)

Author keywords

Action potential; Langendorff isolated heart; Preclinical models; Proarrhythmia; Purkinje fiber; QT prolongation; Rabbit

Indexed keywords

DOFETILIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; EXTRASYSTOLE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART PACING; HEART PROARRHYTHMIA; HEART REPOLARIZATION; IN VITRO STUDY; ISOLATED HEART; MALE; MEMBRANE POTENTIAL; MICROELECTRODE; NONHUMAN; PURKINJE FIBER; QRS COMPLEX; QT INTERVAL; RABBIT; T WAVE; TEMPERATURE SENSITIVITY;

ORYCTOLAGUS CUNICULUS;

EID: 77952292550     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.01.011     Document Type: Article

References (40)

1. Aktas M.K., Shah A.H., Akiyama T. Dofetilide-induced long QT and Torsades de Pointes. Annals of Noninvasive Electrocardiology 2007, 12(3):197-202.
2. Allen M.J., Nichols D.J., Oliver S.D. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. British Journal of Clinical Pharmacology 2000, 50(3):247-253.
3. Antzelevitch C. Arrhythmogenic mechanism of QT prolonging drugs: Is QT prolongation really the problem?. Journal of Electrocardiology 2004, 37(supplement 1):15-24.
4. Antzelevitch C. Heterogeneity and cardiac arrthythmias: An overview. Heart Rhythm 2007, 4:964-972.
5. Antzelevitch C., Yan G.-X., Shimizu W. Transmural dispersion of repolarization and arrhythmogenicity. Journal of Electrocardiology 1999, 32(supplement 1):158-165.
6. Antzelevitch C., Zygmunt A.C., Fish J., Perez G., Scornik F. How do we measure repolarisation inside the heart?. Contemporary cardiology: Cardiac repolarization: Bridging basic and clinical science 2003, Humana Press Inc, Totowa, NJ. I. Gussak (Ed.).
7. Aubert M., Osterwalder R., Wagner B., Parrilla I., Cavero I., Doessegger L., et al. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced Torsades de Pointes in humans. Drug Safety 2006, 29(3):237-254.
8. Belardinelli L., Antzelevitch C., Vos M.A. Assessing predictors of drug-induced Torsades de Pointes. Trends in Pharmacological Sciences 2003, 24(12):619-625.
9. Carmeliet E. Voltage- and time-dependent block of the delayed K+current in cardiac myocytes by dofetilide. The Journal of Pharmacology and Experimental Therapeutics 1992, 262(2):809-817.
10. Chen X., Cordes J.S., Bradley J.A., Sun Z., Zhou J. Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drug. Journal of Pharmacological and Toxicological Methods 2006, 54:261-272.
11. Cheng H.C., Incardona J. Models of Torsades de Pointes: Effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. Journal of Pharmacological and Toxicological Methods 2009, 60:174-184.
12. Cheng H.C., Incardona J., Mc Cullough B. Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. Journal of Pharmacological and Toxicological Methods 2006, 54:278-287.
13. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of Torsades de Pointes. European Heart Journal Supplements 2001, 3:K70-K80.
14. Demolis J.-L., Funk-Brentano C., Ropers J., Ghadanfar M., Nichols D.J., Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996, 94:1592-1599.
15. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Archives des Maladies du Cœur et des Vaisseaux 1966, 59:263-272.
16. Dumotier B.M., Adamantidis M.M., Puisieux F.L., Bastide M.M., Dupuis B.A. Repercussions of pharmacologic reduction in ionic currents on action potential configuration in rabbit Purkinje fibers: Are they indicative of proarrhythmic potential?. Drug Development Research 1999, 47:63-76.
17. El-Sherif N., Caref E.B., Yin H., Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: Tridimensional mapping of activation and recovery patterns. Circulation Research 1996, 79:474-492.
18. El-Sherif N., Chinushi M., Caref E.B., Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of Torsades de Pointes tachyarrhythmias in the long-QT syndrome. Detailed analysis of ventricular tridimensional activation patterns. Circulation 1997, 96:4392-4399.
19. Fish J.M., Di Diego J.M., Nesterenko V., Antzelevitch C. Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization. Implications for biventricular pacing. Circulation 2004, 109:2136-2142.
20. Guillon, J.-M., Roche, M., Ballet, V., and Doubovetzky, M. Electrocardiographic effects of moxifloxacin, quinidine and quinimax on a Langendorff-perfused rabbit heart model. Journal of Pharmacological and Toxicological Methods, abstract in press.
21. Guo D., Zhou J., Zhao X., Gupta P., Kowey P.R., Martin J., et al. L-type calcium current recovery versus ventricular repolarization: Preserved membrane-stabilizing mechanism for different QT intervals across species. Heart Rhythm 2008, 5:271-279.
22. Habbab M.-D.A., El Sherif N. Drug-induced Torsades de Pointes: Role of early afterdepolarizations and dispersion of repolarization. American Journal of Medicine 1990, 89:241-246.
23. Hondeghem L.M., Lu H.R., Van Rossem K., De Clerck F. Detection of proarrhythmia in the female rabbit heart: Blinded validation. Journal of Cardiovascular Electrophysiology 2003, 14:287-294.
24. Jurkiewicz N.K., Sanguinetti M.C. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circulation Research 1993, 72:75-83.
25. Kadish A. What is a monophasic action potential?. Cardiovascular Research 2004, 63:580-581.
26. Kondo M., Nesterenko V., Antzelevitch C. Cellular basis for the monophasic action potential. Which electrode is the recording electrode?. Cardiovascular Research 2004, 63:635-644.
27. Lawrence C.L., Bridgland-Taylor M.H., Pollard C.E., Hammond T.G., Valentin J.-P. A rabbit Langendorff heart proarrhythmia model: Predictive value for clinical identification of Torsades de Pointes. British Journal of Pharmacology 2006, 149:845-860.
28. Le Coz F., Funk-Brentano C., Morell T., Ghadanfar M.M., Jaillon P. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clinical Pharmacology and Therapeutics 1995, 57:533-542.
29. Liu M.D., Choi B.R., Drici M.D., Salama G. Sex modulates the arrhythmogenic substrate in prepubertal rabbit hearts with long QT2. Journal of Cardiovascular Electrophysiology 2005, 16:516-524.
30. Lu H.R., Vlaminckx E., Van Ammel K., De Clerck F. Drug-induced long QT in isolated rabbit Purkinje fibers: Importance of action potential duration, triangulation and early afterdepolarizations. European Journal of Pharmacology 2002, 452:183-192.
31. Milberg P., Hilker E., Ramtin S., Cakir Y., Stypmann J., Engelen M.A., et al. Proarrhythmia as a class effect of quinolones: Increased dispersion of repolarization and triangulation of action potential predict Torsades de Pointes. Journal of Cardiovascular Electrophysiology 2007, 18(6):647-654.
32. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 2008, 154:1382-1399.
33. Rampe D., Roy M.L., Dennis A., Brown A.M. A mechanism for the proarrhythmic effects of Cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel hERG. FEBS Letters 1997, 417(1):28-32.
34. Sims C., Reisenweber S., Viswanathan P.C., Choi B.R., Walker W.H., Salama G. Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with drug-induced long QT type 2. Circulation Research 2008, 102:e86-e100.
35. Snyders D.J., Chaudhary A. High affinity open channel block by dofetilide of hERG expressed in a human cell line. Molecular Pharmacology 1996, 49:949-955.
36. Steidl-Nichols J.V., Hanton G., Leaney J., Liu R.-C., Leishman D., McHarg A., et al. Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model. Journal of Pharmacological and Toxicological Methods 2008, 57:9-22.
37. Tord-Pedersen C., Møller M., Bloch-Thomsen P.E., Køber L., Sandøe E., Egstrup K., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. The New England Journal of Medicine 1999, 341(12):857-865.
38. Yan G.-X., Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998, 98:1928-1936.
39. Yan G.-X., Lankipalli R.S., Burke J.F., Musco S., Kowey P.R. Ventricular repolarization components on the electrocardiogram, cellular basis and clinical significance. Journal of the American College of Cardiology 2003, 42(3):401-409.
40. Zareba W., Moss A.J., Locati E.H., Lehmann M.H., Peterson D.R., Hall W.J., et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology 2003, 42:103-109.